Published in Endocr Connect on January 15, 2016
Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Endocr Pract (2011) 3.40
A randomized comparison of radioiodine doses in Graves' hyperthyroidism. J Clin Endocrinol Metab (2003) 2.72
Optimal iodine-131 dose for eliminating hyperthyroidism in Graves' disease. J Nucl Med (1991) 2.36
Ablative radioiodine therapy for hyperthyroidism: long term follow up study. Br Med J (Clin Res Ed) (1984) 2.22
Long-term follow-up of treatment of thyrotoxicosis by three different methods. Clin Endocrinol (Oxf) (1991) 1.57
Thyroid stunning. Thyroid (2003) 1.48
Current trends in the management of Graves' disease. J Clin Endocrinol Metab (1990) 1.39
Radioiodine therapy in benign thyroid diseases: effects, side effects, and factors affecting therapeutic outcome. Endocr Rev (2012) 1.34
Optimization of radioiodine therapy of thyrotoxicosis: what have we learned after 50 years? J Nucl Med (1993) 1.22
The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves' hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab (2001) 1.16
Radioiodine therapy compared in patients with toxic nodular or Graves' hyperthyroidism. QJM (1995) 1.14
Is calculation of the dose in radioiodine therapy of hyperthyroidism worth while? Clin Endocrinol (Oxf) (1995) 1.11
Success rate of radioiodine therapy in Graves' disease: the influence of thyrostatic medication. J Clin Endocrinol Metab (1999) 1.08
Optimized radioiodine therapy of Graves' disease: analysis of the delivered dose and of other possible factors affecting outcome. Eur J Endocrinol (1999) 0.98
Outcome of 131I therapy in hyperthyroidism using a 550MBq fixed dose regimen. Ulster Med J (2013) 0.96
The predictive role of 24h RAIU with respect to the outcome of low fixed dose radioiodine therapy in patients with diffuse toxic goiter. Hormones (Athens) (2013) 0.90
A reappraisal of the role of methimazole and other factors on the efficacy and outcome of radioiodine therapy of Graves' hyperthyroidism. J Endocrinol Invest (1990) 0.88
Reduced iodide transport (stunning) and DNA synthesis in thyrocytes exposed to low absorbed doses from 131I in vitro. J Nucl Med (2007) 0.87
Study of the correlation between administered activity and radiation committed dose to the thyroid in 131I therapy of Graves' disease. Radiat Prot Dosimetry (2001) 0.86
Radioiodine therapy in hyperthyroidism: inverse correlation of pretherapeutic iodine uptake level and post-therapeutic outcome. Eur J Clin Invest (2004) 0.86
The various effects of amiodarone on thyroid function. Thyroid (2001) 0.86
Treatment with propylthiouracil before radioactive iodine therapy is associated with a higher treatment failure rate than therapy with radioactive iodine alone in Graves' disease. Thyroid (1995) 0.86
Thionamides alter the efficacy of radioiodine treatment in patients with Graves' disease. South Med J (1995) 0.83
Effect of pretreatment with carbimazole in patients with thyrotoxicosis subsequently treated with radioactive iodine. Br Med J (1969) 0.82
Graves' disease radioiodine-therapy: choosing target absorbed doses for therapy planning. Med Phys (2014) 0.82
Radioiodine therapy in patients with Graves' disease and the effects of prior carbimazole therapy. Indian J Endocrinol Metab (2014) 0.82
The action of methimazole and L-thyroxine in radioiodine therapy: a prospective study on the incidence of hypothyroidism. Thyroid (1995) 0.79
Radioiodine therapy in hyperthyroid disease: poorer outcome in patients with high 24 hours radioiodine uptake. Clin Physiol Funct Imaging (2006) 0.79
Radioiodine treatment of hyperthyroidism in patients with low thyroid uptake. Nucl Med Rev Cent East Eur (2005) 0.78
Long-term carbimazole intake does not affect success rate of radioactive 131Iodine in treatment of Graves' hyperthyroidism. Nucl Med Commun (2008) 0.78
Factors influencing the success of radioiodine therapy in patients with Graves' disease. Nucl Med Commun (2015) 0.77
Comparison of clinical outcome after a fixed dose versus dosimetry-based radioiodine treatment of Graves' disease: Results of a randomized controlled trial in Indian population. Indian J Endocrinol Metab (2014) 0.77
Decreased radioiodine uptake of FRTL-5 cells after (131)I incubation in vitro: molecular biological investigations indicate a cell cycle-dependent pathway. Eur J Nucl Med Mol Imaging (2008) 0.77